Skip to main content

Table 1 Demographics and clinical characteristics of patients in the training and validation cohort

From: A multi-parametric prognostic model based on clinical features and serological markers predicts overall survival in non-small cell lung cancer patients with chronic hepatitis B viral infection

Characteristic

Training cohort

Validation cohort

P value

n = (145)

n = (56)

No. (%)

No. (%)

Gender

  

0.811

 Male

109 (75.2%)

43 (76.8%)

 

 Female

36 (24.8%)

13 (23.2%)

 

Age (years)

  

0.431

 ≤ 40

15 (10.3%)

8 (14.3%)

 

 > 40

130 (89.7%)

48(85.7%)

 

Family history

  

0.898

 Yes

35 (24.1%)

14 (25.0%)

 

 No

110 (75.9%)

42 (75.0%)

 

Smoking behavior

  

0.819

 Yes

88 (60.7%)

33 (58.9%)

 

 No

57 (39.3%)

23 (41.1%)

 

BMI (kg/m2)

  

0.630

 ≤ 22.3

80 (55.2%)

33 (58.9%)

 

 > 22.3

65 (44.8%)

23 (41.1%)

 

TNM stagea

  

0.846

 I

34 (23.4%)

11 (19.6%)

 

 II

14 (9.7%)

5 (8.9%)

 

 III

50 (34.5%)

23 (41.1%)

 

 IV

47 (32.4%)

17 (30.4%)

 

Size (cm)b

  

0.911

 ≤ 4.0

79 (54.5%)

31 (55.4%)

 

 > 4.0

66 (45.5%)

25 (44.6%)

 

Treatment

  

0.648

 Sur

31 (21.4%)

13 (23.2%)

 

 Sur and Rad/Che

47 (32.4%)

18 (32.1%)

 

 Rad/Che

54 (37.2%)

17 (30.4%)

 

 Other

13 (9.0%)

8 (14.3%)

 

WBC (10 9/L)

  

0.560

 ≤ 10.8

125 (86.2%)

50 (89.3%)

 

 > 10.8

20 (13.8%)

6 (10.7%)

 

Neutrophils (109/L)

   

 ≤ 8.1

128 (88.3%)

51 (91.1%)

0.569

 > 8.1

17 (11.7%)

5 (8.9%)

 

Lymphocyte (109/L)

   

 ≤ 1.74

40 (27.6%)

17 (30.4%)

0.696

 > 1.74

105 (72.4%)

39 (69.6%)

 

Platelet (109/L)

  

0.245

 ≤ 163.0

22 (15.2%)

5 (8.9%)

 

 > 163.0

123 (84.8%)

51 (91.1%)

 

NLR

  

0.521

 ≤ 2.7

90 (62.1%)

32 (57.1%)

 

 > 2.7

55 (37.9%)

24 (42.9%)

 

PLR

  

0.043

 ≤ 108.6

64 (44.1%)

16 (28.6%)

 

 > 108.6

81 (55.9%)

40 (71.4%)

 

HBsAb

  

0.107

 Negative

145 (100.0%)

55 (98.2%)

 

 Positive

0 (0.0%)

1 (1.8%)

 

HBeAg

  

0.026

 Negative

142 (97.9%)

51 (91.1%)

 

 Positive

3 (2.1%)

5 (8.9%)

 

HBeAb

  

0.016

 Negative

8 (5.5%)

9 (16.1%)

 

 Positive

137 (94.5%)

47 (83.9%)

 

HBcAb

  

0.022

 Negative

0 (0.0%)

2 (3.6%)

 

 Positive

145 (100.0%)

54 (96.4%)

 

ALB (g/L)

  

0.035

 ≤ 42.5

91 (62.8%)

26 (46.4%)

 

 > 42.5

54 (37.2%)

30 (53.6%)

 

ALT (U/L)

  

0.260

 ≤ 13.7

26 (17.9%)

14 (25.0%)

 

 > 13.7

119 (82.1%)

42 (75.0%)

 

AST (U/L)

  

0.370

 ≤ 32.2

124 (85.5%)

45 (80.4%)

 

 > 32.2

21 (14.5%)

11 (19.6%)

 

SLR

  

0.987

 ≤ 1.5

127 (87.6%)

49 (87.5%)

 

 > 1.5

18 (12.4%)

7 (12.5%)

 

ALP (U/L)

  

0.931

 ≤ 69.6

56 (38.6%)

22 (39.3%)

 

 > 69.6

89 (61.4%)

34 (60.7%)

 

APOA (g/L)

  

0.425

 ≤ 1.2

79 (54.5%)

27 (48.2%)

 

 > 1.2

66 (45.5%)

29 (51.8%)

 

APOB (g/L)

  

0.315

 ≤ 1.0

101 (69.7%)

43 (76.9%)

 

 > 1.0

44 (30.3%)

13 (23.2%)

 

ABR

  

0.057

 ≤ 0.8

14 (9.7%)

1 (1.8%)

 

 > 0.8

131 (90.3%)

55 (98.2%)

 

CRP (mg/L)

  

0.443

 ≤ 6.2

82 (56.6%)

35 (62.5%)

 

 > 6.2

63 (43.6%)

21 (37.5%)

 

CAR

  

0.278

 ≤ 0.16

81 (17.9%)

36 (64.3%)

 

 > 0.16

64 (44.1%)

20 (35.7%)

 

LDH (U/L)

  

0.755

 ≤ 230.3

119 (82.1%)

47 (83.9%)

 

 > 230.3

26 (17.9%)

9 (16.1%)

 

GGT (U/L)

  

0.731

 ≤ 44.2

116 (80.0%)

46 (82.1%)

 

 > 44.2

29 (20.0%)

10 (17.9%)

 

TBIL (umol/L)

  

0.652

 ≤ 15.4

115 (79.3%)

46 (82.1%)

 

 > 15.4

30 (20.7%)

10 (17.9%)

 

DBIL (umol/L)

  

0.813

 ≤ 3.0

57 (39.3%)

21 (37.5%)

 

 > 3.0

88 (60.7%)

35 (62.5%)

 

PNI

  

0.084

 ≤ 48.1

34 (23.4%)

7 (12.5%)

 

 > 48.1

111 (76.6%)

49 (87.5%)

 

PI

  

0.521

 0

92 (63.4%)

40 (71.4%)

 

 1

39 (26.9%)

11 (19.7%)

 

 2

14 (9.7%)

5 (8.9%)

 

GPS

  

0.456

 0

93 (64.1%)

41 (73.2%)

 

 1

46 (31.7%)

13 (23.2%)

 

 2

6 (4.1%)

2 (3.6%)

 
  1. BMI body mass index, TNM tumor node metastasis stage, Sur surgery; Rad: radiotherapy, Che chemotherapy, WBC white blood cell, NLR neutrophil/lymphocyte ratio, PLR platelet/lymphocyte ratio, ALB albumin, ALT alanine transaminase, AST aspartate aminotransferase, SLR AST/ALT ratio, ALP alkaline phosphatase, APOA apolipoprotein AI, APOB apolipoprotein B, ABR APOA/APOB ratio, CRP C-reactive protein, CAR C-reactive protein/albumin ratio, LDH lactic dehydrogenase, GGT glutamyl transpeptidase, TBIL total bilirubin, DBIL direct bilirubin, PNI prognostic nutritional index, PI prognostic index, GPS Glasgow prognostic score
  2. aTNM stage was classified according to the AJCC 7th TNM staging system
  3. bThe tumor maximum diameter
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us